|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF2A |
Gene summary for KIF2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF2A | Gene ID | 3796 |
| Gene name | kinesin family member 2A | |
| Gene Alias | CDCBM3 | |
| Cytomap | 5q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O00139 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3796 | KIF2A | LZE4T | Human | Esophagus | ESCC | 3.16e-09 | 3.37e-01 | 0.0811 |
| 3796 | KIF2A | LZE7T | Human | Esophagus | ESCC | 3.57e-07 | 3.88e-01 | 0.0667 |
| 3796 | KIF2A | LZE8T | Human | Esophagus | ESCC | 3.60e-02 | 1.08e-01 | 0.067 |
| 3796 | KIF2A | LZE20T | Human | Esophagus | ESCC | 1.77e-03 | 1.37e-01 | 0.0662 |
| 3796 | KIF2A | LZE24T | Human | Esophagus | ESCC | 1.21e-11 | 3.92e-01 | 0.0596 |
| 3796 | KIF2A | P1T-E | Human | Esophagus | ESCC | 1.23e-12 | 6.07e-01 | 0.0875 |
| 3796 | KIF2A | P2T-E | Human | Esophagus | ESCC | 8.40e-86 | 1.45e+00 | 0.1177 |
| 3796 | KIF2A | P4T-E | Human | Esophagus | ESCC | 1.37e-20 | 4.87e-01 | 0.1323 |
| 3796 | KIF2A | P5T-E | Human | Esophagus | ESCC | 8.29e-13 | 2.73e-01 | 0.1327 |
| 3796 | KIF2A | P8T-E | Human | Esophagus | ESCC | 4.05e-29 | 3.93e-01 | 0.0889 |
| 3796 | KIF2A | P9T-E | Human | Esophagus | ESCC | 8.07e-14 | 2.53e-01 | 0.1131 |
| 3796 | KIF2A | P10T-E | Human | Esophagus | ESCC | 3.58e-25 | 4.37e-01 | 0.116 |
| 3796 | KIF2A | P11T-E | Human | Esophagus | ESCC | 1.96e-14 | 6.03e-01 | 0.1426 |
| 3796 | KIF2A | P12T-E | Human | Esophagus | ESCC | 1.32e-32 | 6.58e-01 | 0.1122 |
| 3796 | KIF2A | P15T-E | Human | Esophagus | ESCC | 4.54e-23 | 5.63e-01 | 0.1149 |
| 3796 | KIF2A | P16T-E | Human | Esophagus | ESCC | 3.94e-48 | 7.47e-01 | 0.1153 |
| 3796 | KIF2A | P17T-E | Human | Esophagus | ESCC | 1.01e-05 | 4.44e-01 | 0.1278 |
| 3796 | KIF2A | P19T-E | Human | Esophagus | ESCC | 6.26e-08 | 4.69e-01 | 0.1662 |
| 3796 | KIF2A | P20T-E | Human | Esophagus | ESCC | 3.20e-36 | 7.95e-01 | 0.1124 |
| 3796 | KIF2A | P21T-E | Human | Esophagus | ESCC | 1.28e-35 | 6.49e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:009030715 | Esophagus | ESCC | mitotic spindle assembly | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:00311094 | Esophagus | ESCC | microtubule polymerization or depolymerization | 77/8552 | 122/18723 | 7.60e-05 | 5.68e-04 | 77 |
| GO:00436245 | Esophagus | ESCC | cellular protein complex disassembly | 78/8552 | 136/18723 | 4.00e-03 | 1.62e-02 | 78 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:000705111 | Liver | HCC | spindle organization | 116/7958 | 184/18723 | 1.40e-08 | 3.40e-07 | 116 |
| GO:000705211 | Liver | HCC | mitotic spindle organization | 80/7958 | 120/18723 | 7.43e-08 | 1.50e-06 | 80 |
| GO:190285011 | Liver | HCC | microtubule cytoskeleton organization involved in mitosis | 93/7958 | 147/18723 | 2.91e-07 | 5.09e-06 | 93 |
| GO:005122511 | Liver | HCC | spindle assembly | 75/7958 | 117/18723 | 1.92e-06 | 2.67e-05 | 75 |
| GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF2A | SNV | Missense_Mutation | rs767638932 | c.182N>T | p.Ser61Leu | p.S61L | O00139 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
| KIF2A | SNV | Missense_Mutation | c.208N>A | p.Glu70Lys | p.E70K | O00139 | protein_coding | tolerated(0.36) | benign(0.155) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| KIF2A | SNV | Missense_Mutation | c.2045N>T | p.Ala682Val | p.A682V | O00139 | protein_coding | tolerated(0.48) | benign(0.001) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KIF2A | SNV | Missense_Mutation | c.1675N>C | p.Asp559His | p.D559H | O00139 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| KIF2A | SNV | Missense_Mutation | c.674G>A | p.Cys225Tyr | p.C225Y | O00139 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KIF2A | SNV | Missense_Mutation | c.72N>G | p.Ile24Met | p.I24M | O00139 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD | |
| KIF2A | insertion | In_Frame_Ins | novel | c.1307_1308insGTCCTT | p.His436delinsGlnSerPhe | p.H436delinsQSF | O00139 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| KIF2A | insertion | Frame_Shift_Ins | novel | c.1309_1310insAAACTTTTCAACTT | p.Ala437GlufsTer55 | p.A437Efs*55 | O00139 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| KIF2A | SNV | Missense_Mutation | c.177N>G | p.Ile59Met | p.I59M | O00139 | protein_coding | deleterious(0) | possibly_damaging(0.805) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| KIF2A | SNV | Missense_Mutation | c.1741N>G | p.Phe581Val | p.F581V | O00139 | protein_coding | tolerated(0.52) | probably_damaging(0.943) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |